Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3845MR)

This product GTTS-WQ3845MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3845MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5633MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ5616MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ8874MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ2172MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ5217MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ7126MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ3721MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ6614MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW